Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of GST-HG171 in Renal Impairment
NCT06106126Phase 1Unknown
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of atilotrelvir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Fujian Akeylink Biotechnology Co., Ltd. Primary endpoint: Maximum observed plasma concentration. Status: unknown.
02
Drugs
atilotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06106126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106126.